72 kDa Type IV Collagenase - Pipeline Review, H2 2019
72 kDa Type IV Collagenase - Pipeline Review, H2 2019
SUMMARY
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report 72 kDa Type IV Collagenase - Pipeline Review, H2 2019, outlays comprehensive information on the 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - 72 kDa type IV collagenase or matrix metalloproteinase-2 (MMP-2) and gelatinase A is an enzyme encoded by the MMP2 gene. It is an Ubiquitinous metalloproteinase. It is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. It plays an important role in myocardial cell death pathways. It contributes to myocardial oxidative stress by regulating the activity of GSK3beta.
The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology and Cardiovascular which include indications Neuropathic Pain (Neuralgia), Cancer Pain, Diabetic Neuropathic Pain, Melanoma, Metastatic Melanoma, Myocardial Infarction, Opium (Opioid) Addiction, Osteoarthritis Pain, Peripheral Neuropathy (Sensory Neuropathy) and Postherpetic Neuralgia.
Furthermore, this report also reviews key players involved in 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report 72 kDa Type IV Collagenase - Pipeline Review, H2 2019, outlays comprehensive information on the 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - 72 kDa type IV collagenase or matrix metalloproteinase-2 (MMP-2) and gelatinase A is an enzyme encoded by the MMP2 gene. It is an Ubiquitinous metalloproteinase. It is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. It plays an important role in myocardial cell death pathways. It contributes to myocardial oxidative stress by regulating the activity of GSK3beta.
The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology and Cardiovascular which include indications Neuropathic Pain (Neuralgia), Cancer Pain, Diabetic Neuropathic Pain, Melanoma, Metastatic Melanoma, Myocardial Infarction, Opium (Opioid) Addiction, Osteoarthritis Pain, Peripheral Neuropathy (Sensory Neuropathy) and Postherpetic Neuralgia.
Furthermore, this report also reviews key players involved in 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24)
- The report reviews 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) targeted therapeutics and enlists all their major and minor projects
- The report assesses 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Overview
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Companies Involved in Therapeutics Development
NeuroMax Ltd
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Drug Profiles
AQU-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQU-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQU-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target MMP2 and MMP9 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Dormant Products
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Discontinued Products
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Product Development Milestones
Featured News & Press Releases
Nov 07, 2018: California research team publishes promising results from peptide based universal cancer vaccine
Jun 28, 2016: NeuroMax Announces Start Phase 1 Clinical Trial of AQU-005 for the Treatment of Neuropathic Pain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Overview
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Companies Involved in Therapeutics Development
NeuroMax Ltd
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Drug Profiles
AQU-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQU-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQU-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target MMP2 and MMP9 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Dormant Products
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Discontinued Products
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Product Development Milestones
Featured News & Press Releases
Nov 07, 2018: California research team publishes promising results from peptide based universal cancer vaccine
Jun 28, 2016: NeuroMax Announces Start Phase 1 Clinical Trial of AQU-005 for the Treatment of Neuropathic Pain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by NeuroMax Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by NeuroMax Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
NeuroMax Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
NeuroMax Ltd
